The estimated Net Worth of Cyril Allouche is at least $78.4 Tysiąc dollars as of 15 March 2019. Cyril Allouche owns over 498 units of Revance Therapeutics Inc stock worth over $42,112 and over the last 6 years Cyril sold RVNC stock worth over $36,300.
Cyril has made over 6 trades of the Revance Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Cyril sold 498 units of RVNC stock worth $7,709 on 15 March 2019.
The largest trade Cyril's ever made was exercising 2,188 units of Revance Therapeutics Inc stock on 9 November 2018 worth over $29,210. On average, Cyril trades about 415 units every 23 days since 2018. As of 15 March 2019 Cyril still owns at least 6,400 units of Revance Therapeutics Inc stock.
You can see the complete history of Cyril Allouche stock trades at the bottom of the page.
Cyril's mailing address filed with the SEC is 7555 Gateway Blvd, Newark, CA 94560, USA.
Over the last 11 years, insiders at Revance Therapeutics Inc have traded over $29,070,398 worth of Revance Therapeutics Inc stock and bought 136,530 units worth $2,014,047 . The most active insiders traders include Vlad Coric, Julian S Gangolli oraz Angus C. Russell. On average, Revance Therapeutics Inc executives and independent directors trade stock every 31 days with the average trade being worth of $83,132. The most recent stock trade was executed by Erica Jordan on 16 April 2024, trading 2,392 units of RVNC stock currently worth $9,090.
revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form
Revance Therapeutics Inc executives and other stock owners filed with the SEC include: